Vimal H. Prajapati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vimal H. Prajapati has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
Jensen Yeung
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada; Probity Medical Research, Waterloo, Canada; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Canada; Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
15 shared publicationsAlim R. Devani
Skin Health & Wellness Centre, Calgary, Canada
13 shared publicationsBrian D. Rankin
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Canada
12 shared publications- Charles W. Lynde
University of Toronto, Markham, Canada
10 shared publications Abrahim Abduelmula
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada
9 shared publications- Siddhartha Sood
Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada
9 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Springer Nature in Dermatology and Therapy
- p. 1-21
Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project
- 19 October 2026
- Published by Springer Nature in Dermatology and Therapy
- p. 1-21
Open AccessInitiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project
- Open Access
- 6 October 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (11) , 5727-5741
Canadian Expert Consensus Recommendations on the Use of Photodynamic Therapy in Actinic Keratosis
- 6 October 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (11) , 5727-5741
Open AccessCanadian Expert Consensus Recommendations on the Use of Photodynamic Therapy in Actinic Keratosis
- Open Access
- 11 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (10) , 5195-5214
Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study
- 11 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (10) , 5195-5214
Open AccessReal-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study
- Open Access
- 11 June 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 2662191
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary
- 11 June 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 2662191
Open AccessLong-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary
- Open Access
- 16 April 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (6) , 2931-2946
Canadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS)
Treat-to-target (T2T) strategies have been proposed to support decision-making in chronic plaque psoriasis care, but their use in Canadian clinical practice has not been well studied. This retrospective chart review examined how Canadian T2T criteria are applied for adult patients with moderate-to-severe plaque psoriasis and whether treatment decisions reflect treatment target achievement in clinical practice. Charts from 438 adults who initiated or modified biologic therapy and completed two visits 3-8 months apart were included. Treatment target achievement at visit 2 was assessed using predefined major and minor criteria, which included Psoriasis Area and Severity Index (PASI), body surface area (BSA), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) outcome measures. Of the 438 patients, 321 (73.3%) met the treatment target and 98.4% of these continued their current biologic therapy. Among the 117 patients who did not meet the treatment target, 48.7% of remained on their current biologic therapy. Treatment target achievement was associated with lower PASI, BSA, PGA, and DLQI scores. DLQI influenced treatment modification even when treatment targets were unmet. Switching between interleukin (IL)-17 and IL-23 inhibitors was the most frequent treatment modification strategy. Findings support the clinical value of Canadian T2T criteria, while highlighting the importance of shared decision-making. Many patients who did not meet treatment targets remained on their current biologic therapy, emphasizing the role of patient input, quality of life, and physician judgment. These results reinforce the importance of balancing treatment targets with individualized care in real-world plaque psoriasis management.
- 16 April 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (6) , 2931-2946
Open AccessCanadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS)
Treat-to-target (T2T) strategies have been proposed to support decision-making in chronic plaque psoriasis care, but their use in Canadian clinical practice has not been well studied. This retrospective chart review examined how Canadian T2T criteria are applied for adult patients with moderate-to-severe plaque psoriasis and whether treatment decisions reflect treatment target achievement in clinical practice. Charts from 438 adults who initiated or modified biologic therapy and completed two visits 3-8 months apart were included. Treatment target achievement at visit 2 was assessed using predefined major and minor criteria, which included Psoriasis Area and Severity Index (PASI), body surface area (BSA), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) outcome measures. Of the 438 patients, 321 (73.3%) met the treatment target and 98.4% of these continued their current biologic therapy. Among the 117 patients who did not meet the treatment target, 48.7% of remained on their current biologic therapy. Treatment target achievement was associated with lower PASI, BSA, PGA, and DLQI scores. DLQI influenced treatment modification even when treatment targets were unmet. Switching between interleukin (IL)-17 and IL-23 inhibitors was the most frequent treatment modification strategy. Findings support the clinical value of Canadian T2T criteria, while highlighting the importance of shared decision-making. Many patients who did not meet treatment targets remained on their current biologic therapy, emphasizing the role of patient input, quality of life, and physician judgment. These results reinforce the importance of balancing treatment targets with individualized care in real-world plaque psoriasis management.
- 19 March 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (2_suppl)
Current and Future Management of Chronic Hand Eczema in Canada: Evolving Treatment Paradigms
The chronic hand eczema (CHE) management landscape is rapidly evolving with emerging evidence supporting the efficacy and safety of new treatments, some of which are not included in current guidelines. Preventive measures remain a cornerstone in the management of CHE across all etiological and morphological subtypes. The array of topical therapies for CHE is expanding with mounting evidence for newer agents that directly target the underlying pathophysiology of CHE compared to older agents that are more broadly anti-inflammatory. Phototherapy remains an effective option for CHE, but access and inconvenience remain barriers in many regions. Several advances in targeted systemic therapies for CHE have been made, with some agents approved for the treatment of moderate-to-severe atopic dermatitis exhibiting efficacy in hand and foot eczema, while other agents have evidence specifically for efficacy in CHE. With this evolving treatment landscape, an updated algorithm for the management of CHE is proposed.
- 19 March 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (2_suppl)
Current and Future Management of Chronic Hand Eczema in Canada: Evolving Treatment Paradigms
The chronic hand eczema (CHE) management landscape is rapidly evolving with emerging evidence supporting the efficacy and safety of new treatments, some of which are not included in current guidelines. Preventive measures remain a cornerstone in the management of CHE across all etiological and morphological subtypes. The array of topical therapies for CHE is expanding with mounting evidence for newer agents that directly target the underlying pathophysiology of CHE compared to older agents that are more broadly anti-inflammatory. Phototherapy remains an effective option for CHE, but access and inconvenience remain barriers in many regions. Several advances in targeted systemic therapies for CHE have been made, with some agents approved for the treatment of moderate-to-severe atopic dermatitis exhibiting efficacy in hand and foot eczema, while other agents have evidence specifically for efficacy in CHE. With this evolving treatment landscape, an updated algorithm for the management of CHE is proposed.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Addressing Unmet Needs in Prurigo Nodularis: Expert Canadian Dermatology Perspectives
Prurigo nodularis (PN) is a distinct chronic, inflammatory, neuroimmune‐mediated skin condition characterized by pruritic, often symmetrically distributed nodules, papules, and/or plaques. Recognition of PN as a distinct entity is complicated by the absence of a precise disease definition, uncertain epidemiologic estimates, and limited assessments of disease burden. The aim of this review is to provide a critical overview of global epidemiologic data of PN and current disease definitions. The available diagnostic criteria and assessment tools to determine disease severity for PN are examined. The psychosocial and healthcare burden of PN is also reviewed. Finally, other prevailing shortcomings in this therapeutic area are discussed, including the need for a standardized treatment algorithm for PN using currently available therapies, a greater understanding of disease pathophysiology, and the development of new targeted therapies for PN.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessAddressing Unmet Needs in Prurigo Nodularis: Expert Canadian Dermatology Perspectives
Prurigo nodularis (PN) is a distinct chronic, inflammatory, neuroimmune‐mediated skin condition characterized by pruritic, often symmetrically distributed nodules, papules, and/or plaques. Recognition of PN as a distinct entity is complicated by the absence of a precise disease definition, uncertain epidemiologic estimates, and limited assessments of disease burden. The aim of this review is to provide a critical overview of global epidemiologic data of PN and current disease definitions. The available diagnostic criteria and assessment tools to determine disease severity for PN are examined. The psychosocial and healthcare burden of PN is also reviewed. Finally, other prevailing shortcomings in this therapeutic area are discussed, including the need for a standardized treatment algorithm for PN using currently available therapies, a greater understanding of disease pathophysiology, and the development of new targeted therapies for PN.